logo-loader
Mining
Latrobe Magnesium Ltd

Latrobe Magnesium expects to complete Pre–Feasibility Study in August at magnesium project

au_australia_map_350_4de3021d882a6.jpg

Latrobe Magnesium (ASX: LMG) has decided to temporarily defer a Pre-Feasibility Study at the Latrobe Magnesium Project located in Victoria’s Latrobe Valley.

Interestingly, the company has decided to evaluate a new reagent system with the potential to further increase iron removal, beyond levels previously achieved, deferring the Pre-Feasibility Study while this evaluation is in progress.

The Pre-Feasibility Study will now commence on the basis of the original reagent system with the expected completion of the study in August.

Taking into consideration the latest improvement with the success of the new reagent may adjust the study at a later date. 

The thermodynamic modelling has indicated a significant reduction in the iron content in the beneficiated ash which in turn will reduce ferrosilicon usage in the thermal reduction process.

The evaluation requires Metcon Laboratory to conduct further test work as these tests are inconclusive and will need to undergo repetition with more sophisticated equipment.

The company is presently investigating the use of other suitable facilities.

Latrobe has been tendering a number of major engineering companies over the last month to assist with its study.

 

Quick facts: Latrobe Magnesium Ltd

Price: $0.01

Market: ASX
Market Cap: $6.48 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Kazia Therapeutics reaches milestone for Phase 1 Cantrixil trial in ovarian...

Kazia Therapeutics Limited (ASX:KZA) chief executive officer Dr James Garner updates Proactive Investors on a milestone for the company, with the completion of recruitment for Cantrixil its Phase 1 clinical trial in ovarian cancer. The CEO said the first part of the study has shown some very...

3 hours, 49 minutes ago

2 min read